Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum
- PMID: 8758143
- DOI: 10.1080/00034983.1996.11813054
Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum
Abstract
A sensitive, culture-based, microtitration technique has recently been developed for determining parasite burdens in organs recovered from Balb/c mice infected with Leishmania infantum. In the present study, this technique was used to examine the efficacy of three, first-line, antileishmanial agents in reducing parasite burdens and eradicating parasites from target organs in mice. Treatment with meglumine antimoniate (50 mg SbV/kg.day) significantly reduced the parasite burdens in the livers and lungs (by about 10-fold and > 100-fold, respectively) but not those in the spleens. Although use of a higher dose of meglumine antimoniate (200 mg SbV/kg.day) resulted in an even more dramatic reduction in the parasite burdens in the livers, it had no significant effect on the burdens in the spleens. Treatment with amphotericin B (0.8 mg/kg every other day) resulted in significant reductions in the parasite burdens in the livers, spleens and lungs of infected mice. Although low doses of aminosidine (20 mg/kg.day) had no effect, high doses (200 mg/kg.day) resulted in undetectable parasite burdens in the livers, for at least 100 days post-treatment, and marked reductions in burdens in the spleens. These results are consistent with previous data from studies using animal models of visceral leishmaniasis. Thanks to the sensitivity of the technique, culture microtitration revealed that none of the drug schedules achieved the elimination of all parasites in all target organs. The murine model used mimics some important features of HIV/Leishmania infantum co-infections in humans.
Similar articles
-
Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.J Antimicrob Chemother. 1997 Aug;40(2):287-9. doi: 10.1093/jac/40.2.287. J Antimicrob Chemother. 1997. PMID: 9301998
-
Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.Antimicrob Agents Chemother. 1996 May;40(5):1214-8. doi: 10.1128/AAC.40.5.1214. Antimicrob Agents Chemother. 1996. PMID: 8723469 Free PMC article.
-
Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00962-17. doi: 10.1128/AAC.00962-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28827416 Free PMC article.
-
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.Fundam Clin Pharmacol. 2003 Apr;17(2):183-8. doi: 10.1046/j.1472-8206.2003.00168.x. Fundam Clin Pharmacol. 2003. PMID: 12667228 Review.
-
Recent advances in the treatment of visceral leishmaniasis.Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):130-1, 141. doi: 10.1016/0035-9203(93)90457-2. Trans R Soc Trop Med Hyg. 1993. PMID: 8393221 Review. No abstract available.
Cited by
-
Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis.Pathogens. 2020 Oct 20;9(10):855. doi: 10.3390/pathogens9100855. Pathogens. 2020. PMID: 33092305 Free PMC article.
-
Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.J Parasit Dis. 2011 Oct;35(2):104-12. doi: 10.1007/s12639-011-0040-9. Epub 2011 May 20. J Parasit Dis. 2011. PMID: 23024489 Free PMC article.
-
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Ther Clin Risk Manag. 2012;8:323-8. doi: 10.2147/TCRM.S30139. Epub 2012 Jun 22. Ther Clin Risk Manag. 2012. PMID: 22802694 Free PMC article.
-
Clinical and experimental advances in treatment of visceral leishmaniasis.Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001. Antimicrob Agents Chemother. 2001. PMID: 11451673 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases